Subclones of bone marrow CD34⁺ cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a hematopoietic malignancy with a prognosis that varies with genetic heterogeneity of hematopoietic stem/progenitor cells (HSPCs). Induction chemotherapy with cytarabine and anthracycline has been the standard care for newly diagnosed AML, but about 30% of patients have no response to this regimen. The resistance mechanisms require deeper understanding.

Methods

In our study, using single-cell RNA sequencing, we analyzed the heterogeneity of bone marrow CD34⁺ cells from newly diagnosed patients with AML who were then divided into sensitive and resistant groups according to their responses to induction chemotherapy with cytarabine and anthracycline. We verified our findings by TCGA database, GEO datasets, and multiparameter

SUBMITTER: Jia R 

PROVIDER: S-EPMC9828578 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature